Cited by 1,059Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Open access

Turke, Alexa B., Zejnullahu, Kreshnik, Wu, Yi-Long, Song, Youngchul, Dias-Santagata, Dora, Lifshits, Eugene, Toschi, Luca, Rogers, Andrew, Mok, Tony, Sequist, Lecia, Lindeman, Neal I., Murphy, Carly, Akhavanfard, Sara, Yeap, Beow Y., Xiao, Yun, Capelletti, Marzia, Iafrate, A. John, Lee, Charles, Christensen, James G., Engelman, Jeffrey A., Jänne, Pasi A.·2010·Cancer Cell

DOI 10.1016/j.ccr.2009.11.022PMC PMC2980857

Open this paper in CoChat — free account Open PDF

Abstract

MET amplification activates ERBB3/PI3K/AKT signaling in EGFR mutant lung cancers and causes resistance to EGFR kinase inhibitors. We demonstrate that MET activation by its ligand, HGF, also induces drug resistance, but through GAB1 signaling. Using high-throughput FISH analyses in both cell lines and in patients with lung cancer, we identify subpopulations of cells with MET amplification prior to drug exposure. Surprisingly, HGF accelerates the development of MET amplification both in vitro and in vivo. EGFR kinase inhibitor resistance, due to either MET amplification or autocrine HGF production, was cured in vivo by combined EGFR and MET inhibition. These findings highlight the potential to prospectively identify treatment naive, patients with EGFR-mutant lung cancer who will benefit from initial combination therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2009.11.022

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citation
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“Secondary mutations in EGFR itself, including the EGFR T790M ‘‘gatekeeper’’ mutation is observed in 50% of resistance cases, and amplification of the MET oncogene is observed in 20% of resistance cases (Balak et al., 2006; Bean et al., 2007; Engelman et al., 2007b; Kobayashi et al., 2005; Kosaka et al., 2006; Pao et a…”
Background
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 2×
“To date, resistance mechanisms have predominately involved secondary genomic alterations in the target kinase that alter either the physical (such as steric hindrance) or biochemical (change in ATP affinity) properties of the receptor and result in drug resistance (Gorre et al., 2001; Shah et al., 2002; Yun et al., 20…”
Background
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
Self-citation

Show all 37 references

Sorted by citations

Items 401–500 of 1,000

Biospecimens, biomarkers, and burgeoning data: the imperative for more rigorous research standards
Poste, G. H. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.09.003 · Cited by 51
MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.
Dey, N., Leyland-Jones, B. R., & De, P. K. (2015) · Europe PMC (PubMed Central) · Cited by 50
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
Rimassa, L., Bozzarelli, S., Pietrantonio, F., Cordio, S., Lonardi, S., Toppo, L., Zaniboni, A., Bordonaro, R., Di Bartolomeo, M., Tomasello, G., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.02.004 · Cited by 50
Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms
Suda, K., Rivard, C. J., Mitsudomi, T., & Hirsch, F. R. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1355243 · Cited by 49
Analysis of genes associated with prognosis of lung adenocarcinoma based on GEO and TCGA databases
Ye, Y., & Tian, X. (2020) · Medicine · doi:10.1097/md.0000000000020183 · Cited by 49
The pharmacological point of view of resistance to therapy in tumors
Damia, G. L. M., & Garattini, S. K. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.008 · Cited by 48
Characterization of Liver Metastasis and Its Effect on Targeted Therapy in EGFR-mutant NSCLC: A Multicenter Study
Jiang, T., Cheng, R., Zhang, G., Su, C., Zhao, C., Li, X., Zhang, J., Wu, F., Chen, X., Gao, G., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.04.015 · Cited by 49
Minnelide: A Novel Therapeutic That Promotes Apoptosis in Non-Small Cell Lung Carcinoma In Vivo
Roušalová, I., Banerjee, S., Sangwan, V., Evenson, K., McCauley, J. A., Kratzke, R. A., Vickers, S. M., Saluja, A. K., & D’Cunha, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077411 · Cited by 48
Epidermal growth factor receptor inhibitors in oncology
Vivanco, I., & Mellinghoff, I. K. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833edbdf · Cited by 48
Emerging drugs for head and neck cancer
Wen, Y., & Grandis, J. R. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1031653 · Cited by 48
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors
Liu, M., Xu, S., Wang, Y., Li, Y., Li, Y., Zhang, H., Liu, H., & Chen, J. (2016) · Oncotarget · doi:10.18632/oncotarget.13069 · Cited by 50
Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer
Xu, J., Wang, J., & Zhang, S. (2017) · Oncotarget · doi:10.18632/oncotarget.21164 · Cited by 52
Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review
Karlsen, E., Kahler, S. L., Tefay, J., Joseph, S. R., & Simpson, F. (2021) · Cells · doi:10.3390/cells10051206 · Cited by 52
Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
Terp, M. G., Jacobsen, K., Molina‐Vila, M. Á., Karachaliou, N., Beck, H. C., Bertrán-Alamillo, J., Giménez-Capitán, A. A., Cardona, A. F., Rosell, R., & Ditzel, H. J. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00208-w · Cited by 46
EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications
Greenall, S. A., Donoghue, J. F., Sinderen, M. L. V., Dubljevic, V., Budiman, S., Devlin, M. G., Street, I. P., Adams, T. E., & Johns, T. G. (2015) · Oncogene · doi:10.1038/onc.2014.448 · Cited by 48
DARPP-32 Increases Interactions Between Epidermal Growth Factor Receptor and ERBB3 to Promote Tumor Resistance to Gefitinib
Zhu, S., Belkhiri, A., & El-Rifai, W. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.070 · Cited by 44
Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy
Wang, M., Padhye, S., Guin, S., Ma, Q., & Zhou, Y.-Q. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.106 · Cited by 47
Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs
Nakata, A., Yoshida, R., Yamaguchi, R., Yamauchi, M., Tamada, Y., Fujita, A., Shimamura, T., Imoto, S., Higuchi, T., Nomura, M., et al. (2015) · Scientific Reports · doi:10.1038/srep13076 · Cited by 47
Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity
Suda, K., & Mitsudomi, T. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1524-7 · Cited by 47
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy
Wang, Y., Tian, P., Xia, L., Li, L., Han, R., Zhu, M., Lizaso, A., Tian, Q., Li, M., Yu, B., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.06.003 · Cited by 48
Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer
Pontier, S. M., Huck, L., White, D. E., Rayment, J. H., Sanguin‐Gendreau, V., Hennessy, B. T., Zuo, D., St‐Arnaud, R., Mills, G. B., Dedhar, S., et al. (2010) · Oncogene · doi:10.1038/onc.2010.86 · Cited by 47
Kinases inhibitors in lung cancer: From benchside to bedside
Singh, P. K., Singh, H., & Silakari, O. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.07.002 · Cited by 47
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
Ninomiya, K., Ohashi, K., Makimoto, G., Tomida, S., Higo, H., Kayatani, H., Ninomiya, T., Kubo, T., Ichihara, E., Hotta, K., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20326-z · Cited by 45
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)
Reckamp, K. L., Frankel, P. H., Ruel, N. H., Mack, P. C., Gitlitz, B. J., Li, T., Koczywas, M., Gadgeel, S. M., Cristea, M. C., Belani, C. P., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00132 · Cited by 46
Tumour heterogeneity and immune-modulation
Jamal‐Hanjani, M., Thanopoulou, E., Peggs, K. S., Quezada, S. A., & Swanton, C. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.04.006 · Cited by 45
Targeting mTOR to Overcome Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer Cells
Fei, S.-J., Zhang, X., Dong, S., Cheng, H., Yi-fang, Z., Huang, L., Zhou, H., Xie, Z., Chen, Z., & Wu, Y.-L. L. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069104 · Cited by 45
Self-citation
Alternative Signaling Pathways as Potential Therapeutic Targets for Overcoming EGFR and c-Met Inhibitor Resistance in Non-Small Cell Lung Cancer
Fong, J., Jacobs, R. J., Moravec, D. N., Uppada, S. B., Botting, G. M., Nlend, M., & Puri, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078398 · Cited by 45
Biomarker development in MET-targeted therapy
Zhang, Y., Du, Z., & Zhang, M. (2016) · Oncotarget · doi:10.18632/oncotarget.8276 · Cited by 45
The Role of Next‐Generation Sequencing in Enabling Personalized Oncology Therapy
Cummings, C., Peters, E. J., Lacroix, L., André, F., & Lackner, M. (2016) · Clinical and Translational Science · doi:10.1111/cts.12429 · Cited by 47
Tumor Heterogeneity in Lymphomas: A Different Breed
Schürch, C. M., Federmann, B., Quintanilla‐Martínez, L., & Fend, F. (2017) · Pathobiology · doi:10.1159/000475530 · Cited by 45
When the MET receptor kicks in to resist targeted therapies
Fernandes, M., Jamme, P., Cortot, A. B., Kherrouche, Z., & Tulasne, D. (2021) · Oncogene · doi:10.1038/s41388-021-01835-0 · Cited by 51
Resisting Resistance
Božić, I., & Nowak, M. A. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-042716-094839 · Cited by 42
Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Botting, G. M., Rastogi, I., Chhabra, G., Nlend, M., & Puri, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136155 · Cited by 46
Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors
Mancini, M., & Yarden, Y. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.018 · Cited by 45
Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
Nanjo, S., Yamada, T., Nishihara, H., Takeuchi, S., Sano, T., Nakagawa, T., Ishikawa, D., Zhao, L., Ebi, H., Yasumoto, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084700 · Cited by 45
Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations
Furcht, C. M., Muñoz-Rojas, A. R., Nihalani, D., & Lazzara, M. J. (2012) · Oncogene · doi:10.1038/onc.2012.240 · Cited by 44
Adapting Clinical Paradigms to the Challenges of Cancer Clonal Evolution
Murugaesu, N., Chew, S. K., & Swanton, C. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.02.026 · Cited by 42
Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer
Phan, A. N. H., Hua, T. N. M., Kim, M.-K., Vo, V. T. A., Choi, J.-W., Kim, H.-W., Rho, J. K., Kim, K. W., & Jeong, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.10581 · Cited by 44
Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease
Yarden, Y., & Wheeler, D. L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2 · Cited by 44
Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells
Sesumi, Y., Suda, K., Mizuuchi, H., Kobayashi, Y., Sato, K., Chiba, M., Shimoji, M., Tomizawa, K., Takemoto, T., & Mitsudomi, T. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.12.012 · Cited by 44
Managing Resistance to EFGR- and ALK-Targeted Therapies
Lovly, C. M., Iyengar, P., & Gainor, J. F. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_176251 · Cited by 43
Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer
Chen, Y. (2013) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2013.01.010 · Cited by 41
Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study
Scagliotti, G. V., Shuster, D. E., Орлов, С. В., von Pawel, J., Shepherd, F. A., Ross, J. S., Wang, Q., Schwartz, B. E., & Akerley, W. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.12.009 · Cited by 43
PET Imaging of Receptor Tyrosine Kinases in Cancer
Wei, W., Ni, D., Ehlerding, E. B., Luo, Q., & Cai, W. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0087 · Cited by 43
PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor–Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation
Wu, D., Wu, T., Chen, C., & Lee, H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2724 · Cited by 42
Overexpression of CD44 is associated with the occurrence and migration of non-small cell lung cancer
Guang-hu, L., Gao, Y., Cui, Y., Zhang, T., Cui, R., Jiang, Y., & Shi, J. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5636 · Cited by 42
Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer
Husain, H., Scur, M. D., Murtuza, A., Bui, N. Q., Woodward, B. D., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0105 · Cited by 44
Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor‐tyrosine kinase inhibitors in patients with EGFR ‐mutant non‐small cell lung cancer
Matsumoto, Y., Sawa, K., Fukui, M., Oyanagi, J., Izumi, M., Ogawa, K., Suzumura, T., Watanabe, T., Kaneda, H., Mitsuoka, S., et al. (2019) · Cancer Science · doi:10.1111/cas.14156 · Cited by 43
Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer
Sacher, A. G., Janne, P. A., & Oxnard, G. R. (2014) · Cancer · doi:10.1002/cncr.28723 · Cited by 42
Significance of c‐ MET overexpression in cytotoxic anticancer drug‐resistant small‐cell lung cancer cells
Ozasa, H., Oguri, T., Maeno, K., Takakuwa, O., Kunii, E., Yagi, Y., Uemura, T., Kasai, D., Miyazaki, M., & Niimi, A. (2014) · Cancer Science · doi:10.1111/cas.12447 · Cited by 41
Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer
Corte, C. M. D., Fasano, M., Papaccio, F., Ciardiello, F., & Morgillo, F. (2014) · Biomedicines · doi:10.3390/biomedicines2040345 · Cited by 41
Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer
Yamada, T., Takeuchi, S., Kita, K., Bando, H., Nakamura, T., Matsumoto, K., & Yano, S. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182398e69 · Cited by 44
MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure
Boccaccio, C., & Comoglio, P. M. (2014) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.09.008 · Cited by 42
Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms
Klingler, S., Guo, B., Yao, J., Yan, H., Zhang, L., Vaseva, A. V., Chen, S., Canoll, P., Horner, J. W., Wang, Y., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3122 · Cited by 40
Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy
Xie, Q. R., Su, Y., Dykema, K. J., Johnson, J. S., Koeman, J. M., Giorgi, V. D., Huang, A., Schlegel, R., Essenburg, C. J., Kang, L., et al. (2013) · Genes & Cancer · doi:10.1177/1947601913501075 · Cited by 41
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer
Tarhini, A. A., Rafique, I., Floros, T., Tran, P. N., Gooding, W. E., Villaruz, L., Burns, T. F., Friedland, D., Petro, D. P., Farooqui, M., et al. (2017) · Cancer · doi:10.1002/cncr.30717 · Cited by 42
Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets
Gong, S., Ren, F., Wu, D., Wu, X., & Wu, C. (2017) · mAbs · doi:10.1080/19420862.2017.1345401 · Cited by 41
Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells
Re, M. D., Arrigoni, E., Restante, G., Passaro, A., Rofi, E., Crucitta, S., de Marinis, F., Paolo, A. D., & Danesi, R. (2018) · Stem Cells · doi:10.1002/stem.2787 · Cited by 41
Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors
Peacock, J. D., Pridgeon, M. G., Tovar, E. A., Essenburg, C. J., Bowman, M. J., Madaj, Z., Koeman, J. M., Boguslawski, E. A., Grit, J. L., Dodd, R. D., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3167 · Cited by 41
Urea Cycle Sustains Cellular Energetics upon EGFR Inhibition in EGFR-Mutant NSCLC
Pham‐Danis, C., Gehrke, S. A., Danis, E. P., Rozhok, A. I., Daniels, M. W., Gao, D., Collins, C., Paola, J. T. D., D’Alessandro, A., & DeGregori, J. V. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1068 · Cited by 41
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
Liao, B.-C., Griesing, S., & Yang, J. C. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919890286 · Cited by 40
MET Amplification in Non-Small Cell Lung Cancer (NSCLC)—A Consecutive Evaluation Using Next-Generation Sequencing (NGS) in a Real-World Setting
Schubart, C., Stöhr, R., Tögel, L., Fuchs, F. S., Sı̂rbu, H., Seitz, G., Seggewiß-Bernhardt, R., Leistner, R., Sterlacci, W., Vieth, M. W., et al. (2021) · Cancers · doi:10.3390/cancers13195023 · Cited by 41
High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis
Gao, H., Guan, M., Sun, Z., & Bai, C. (2015) · Tumor Biology · doi:10.1007/s13277-014-2659-5 · Cited by 42
Enhanced PI3K p110α Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110α-Selective PI3K Inhibitor
Brady, S. W., Zhang, J., Seok, D., Wang, H., & Yu, D. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0518 · Cited by 40
Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer
Lara, M. S., Holland, W. S., Chinn, D. C., Burich, R. A., Lara, P. N., Gandara, D. R., Kelly, K. L., & Mack, P. C. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.11.006 · Cited by 40
MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM
Casaletto, J. B., Geddie, M. L., Abu‐Yousif, A. O., Masson, K., Fulgham, A., Boudot, A. J., Maiwald, T., Kearns, J. D., Kohli, N., Su, S. V., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819085116 · Cited by 40
The conditional nature of gene essentiality
Larrimore, K. E., & Rancati, G. I. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.07.015 · Cited by 39
The genomic landscape of nonsmall cell lung carcinoma in never smokers
Boeckx, B., Shahi, R. B., Smeets, D., Brakeleer, S. D., Decoster, L., Brussel, T. V., Galdermans, D., Vercauter, P., Decoster, L., Alexander, P., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32797 · Cited by 40
Impact of cancer evolution on immune surveillance and checkpoint inhibitor response
Wu, Y., Biswas, D., & Swanton, C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.013 · Cited by 43
Self-citation
Non-small cell lung cancer - genetic predictors
Koudeláková, V., Kneblova, M., Trojanec, R., Drábek, J., & Hajdúch, M. (2013) · Biomedical Papers · doi:10.5507/bp.2013.034 · Cited by 39
Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.
Luo, M., & Fu, L.-W. (2014) · Europe PMC (PubMed Central) · Cited by 38
Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients.
Majem, M., & Remón, J. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.03.09 · Cited by 41
Next-generation sequencing applied to molecular diagnostics
Natrajan, R., & Reis-Filho, J. S. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.11.18 · Cited by 41
Taxane benefit in breast cancer—a role for grade and chromosomal stability
A’Hern, R., Jamal‐Hanjani, M., Szász, A. M., Johnston, S. R. D., Reis-Filho, J. S., Roylance, R. R., & Swanton, C. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.67 · Cited by 39
A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma
Olanich, M. E., & Barr, F. G. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.772136 · Cited by 39
Dual-molecular barcode sequencing detects rare variants in tumor and cell free DNA in plasma
Hirotsu, Y., Otake, S., Ohyama, H., Amemiya, K., Higuchi, R., Oyama, T., Mochizuki, H., Goto, T., & Omata, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-60361-3 · Cited by 38
Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies
Asić, K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.004 · Cited by 38
Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
D’Arcangelo, M., & Cappuzzo, F. (2013) · Biologics · doi:10.2147/btt.s28908 · Cited by 38
Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma
Yoshida, T., Ishii, G., Goto, K., Yoh, K., Niho, S., Umemura, S., Matsumoto, S., Ohmatsu, H., Nagai, K., Ohe, Y., et al. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1495-0 · Cited by 38
Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer
Izar, B., Rotow, J. K., Gainor, J. F., Clark, J. W., & Chabner, B. A. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007807 · Cited by 38
Developing biomarkers to predict benefit from HGF / MET pathway inhibitors
Koeppen, H., Rost, S., & Yauch, R. L. (2013) · The Journal of Pathology · doi:10.1002/path.4268 · Cited by 37
Palmitoylation regulates the intracellular trafficking and stability of c-Met
Coleman, D. T., Gray, A. L., Kridel, S. J., & Cardelli, J. A. (2016) · Oncotarget · doi:10.18632/oncotarget.8706 · Cited by 37
Development of bispecific antibodies in China: overview and prospects
Zhang, J., Yi, J., & Zhou, P. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa011 · Cited by 38
EGFR-activated Src family kinases maintain GAB1-SHP2 complexes distal from EGFR
Furcht, C. M., Buonato, J. M., & Lazzara, M. J. (2015) · Science Signaling · doi:10.1126/scisignal.2005697 · Cited by 37
Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors
Nurwidya, F., Takahashi, F., Murakami, A., Kobayashi, I., Kato, M., Shukuya, T., Tajima, K., Shimada, N., & Takahashi, K. (2013) · Respiratory Investigation · doi:10.1016/j.resinv.2013.07.007 · Cited by 37
Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy
Kim, B., Wang, S., Lee, J. M., Jeong, Y., Ahn, T., Son, D.-S., Park, H. W., Yoo, H.-S., Song, Y.-J., Lee, E., et al. (2014) · Oncogene · doi:10.1038/onc.2014.51 · Cited by 39
Self-citation
MET and ERBB2 Are Coexpressed in ERBB2+ Breast Cancer and Contribute to Innate Resistance
Paulson, A. K., Linklater, E. S., Berghuis, B. D., App, C. A., Oostendorp, L. D., Paulson, J. E., Pettinga, J., Melnik, M. K., Woude, G. F. V., & Graveel, C. R. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0042 · Cited by 38
89Zr-Onartuzumab PET imaging of c-MET receptor dynamics
Pool, M., van Scheltinga, A. G. T. T., Kol, A., Giesen, D., de Vries, E. G. E., & Hooge, M. N. L. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3672-x · Cited by 36
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
Oddo, D., Siravegna, G., Gloghini, A., Vernieri, C., Mussolin, B., Morano, F., Crisafulli, G., Berenato, R., Corti, G., Volpi, C. C., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.196 · Cited by 36
Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution
Jönsson, V. D., Blakely, C. M., Lin, L., Asthana, S., Matni, N., Olivas, V. R., Pazarentzos, E., Gubens, M. A., Bastian, B. C., Taylor, B. S., et al. (2017) · Scientific Reports · doi:10.1038/srep44206 · Cited by 36
DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
Izquierdo, E., Carvalho, D. M., Mackay, A. G., Temelso, S., Boult, J. K. R., Pericoli, G., Fernandez, E., Das, M., Molinari, V., Grabovska, Y., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0930 · Cited by 40
Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance
Xue, Y., Hou, S., Ji, H., & Han, X. (2016) · Protein & Cell · doi:10.1007/s13238-016-0330-1 · Cited by 35
Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC
Li, L., Gu, X., Yue, J., Zhao, Q., Lv, D., Chen, H., & Xu, L. (2017) · Oncotarget · doi:10.18632/oncotarget.21170 · Cited by 36
Nothing in cancer makes sense except…
Greaves, M. F. (2018) · BMC Biology · doi:10.1186/s12915-018-0493-8 · Cited by 36
Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines
Simiczyjew, A., Dratkiewicz, E., Troys, M. V., Ampè, C., Styczeń, I., & Nowak, D. (2018) · Cancers · doi:10.3390/cancers10090335 · Cited by 33
Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
Zhang, Z., Yang, S., & Wang, Q. (2019) · Biomarker Research · doi:10.1186/s40364-019-0179-6 · Cited by 35
Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer
Gini, B., Thomas, N. J., & Blakely, C. M. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.78 · Cited by 38
MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies
Lee, M. H., Jain, P., Wang, F., Ma, P. C., Borczuk, A., & Halmos, B. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1925648 · Cited by 35
Unraveling non-genetic heterogeneity in cancer with dynamical models and computational tools
Pillai, M., Hojel, E., Jolly, M. K., & Goyal, Y. (2023) · Nature Computational Science · doi:10.1038/s43588-023-00427-0 · Cited by 34
ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology
Jacobi, N., Seeboeck, R., Hofmann, E., & Eger, A. (2017) · Cancers · doi:10.3390/cancers9040033 · Cited by 36

Authors: Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., Lindeman, N. I., Murphy, C., Akhavanfard, S., Yeap, B. Y., Xiao, Y., Capelletti, M., Iafrate, A. J., Lee, C., Christensen, J. G., Engelman, J. A., & Jänne, P. A.
Affiliations: Harvard University (US)
Dana-Farber Cancer Institute (US)
Guangdong General Hospital (CN)
Massachusetts General Hospital (US)
Chinese University of Hong Kong (HK)
Brigham and Women's Hospital (US)
Pfizer (United States) (US)
Corresponding author: Engelman, Jeffrey A.
ORCID: Wu, Yi-Long
Song, Youngchul
Dias-Santagata, Dora
Toschi, Luca
Mok, Tony
Sequist, Lecia
Lindeman, Neal I.
Akhavanfard, Sara
Yeap, Beow Y.
Capelletti, Marzia
Iafrate, A. John
Lee, Charles
Christensen, James G.
Engelman, Jeffrey A.
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2010-01
Volume: 17
Issue: 1
Pages: 77-88
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2009.11.022
PMC: PMC2980857
OpenAlex: W1985264867
Cited by: 1,059
References: 37
Citations by year: 2026: 22 · 2025: 31 · 2024: 36 · 2023: 58 · 2022: 41 · 2021: 55 · 2020: 41 · 2019: 56 · 2018: 66 · 2017: 73 · 2016: 93 · 2015: 84 · 2014: 88 · 2013: 94 · 2012: 106
FWCI: 83.75
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1293 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Guangdong Provincial Hospital of Traditional Chinese Medicine
University of Hong Kong
Chinese University of Hong Kong
National Institutes of Health
National Cancer Institute (P50CA127003, R01CA140594, R01CA114465, P50CA090578, R01CA135257, K08CA120060, R01CA137008)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: MET amplification, EGFR mutation, non-small cell lung cancer, hepatocyte growth factor, clonal selection, combination therapy
MeSH terms: Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Gene Amplification, Humans, Lung Neoplasms, Mutation, Proto-Oncogene Proteins, Signal Transduction, Gene Expression, Polymerase Chain Reaction, Hepatocyte Growth Factor, In Situ Hybridization, Fluorescence, Receptors, Growth Factor, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Quinazolinones, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks